Prevalence and Demographic Characteristics of Sarcoidosis in New York City

Robins, Arthur B.; Abeles, Hans; Chaves, Aaron D.

doi:10.1111/j.0954-6820.1964.tb05735.x

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, our estimates reflected diagnosed cases or cases with suspected clinical manifestation and might not be comparable to studies that included people who were asymptomatic (e.g., autopsies or screened population studies). 9,[12][13][14][15][16][17][18] Our primary purpose was to determine the background prevalence of disease for comparison in our cluster investigation. Although case ascertainment methodologies differed for building-and insuranceassociated sarcoidosis cases, they both represented clinically symptomatic diagnosed cases.…”

Section: Limitations and Strengthsmentioning

confidence: 99%

Use of Insurance Claims Data to Determine Prevalence and Confirm a Cluster of Sarcoidosis Cases in Vermont

et al. 2009

View full text Add to dashboard Cite

SYNOPSISObjectives. In 2006, the Vermont Department of Health was asked to respond to a potential cluster of sarcoidosis cases related to a Vermont office building. Sarcoidosis prevalence has not been formally described for the United States. A range of 1-40/100,000 is commonly reported; however, we have not identified primary sources supporting this conclusion. Because of the wide prevalence range and lack of a local estimate, confirming existence of a cluster was difficult.Methods. We ascertained the prevalence of sarcoidosis cases in Vermont by using insurance claims data to determine whether or not a cluster of sarcoidosis cases was related to the office building. We calculated county and state annual prevalence proportions for sarcoidosis for 2004 and 2005 and annual building prevalences for 1992-2006.Results. The pooled sarcoidosis case prevalence for Vermont was 66.1/100,000. The pooled building annual prevalence (1,128/100,000) was statistically different from the county in which the building is located (odds ratio 5 15.5, 95% confidence interval 3.0, 50.3).Conclusions. We reported the first statewide sarcoidosis prevalence in the United States. This prevalence exceeded previous limited and unsubstantiated U.S. reports. Even with Vermont's elevated sarcoidosis prevalence, the presence of a cluster in this building was apparent.

show abstract

Section: Limitations and Strengthsmentioning

confidence: 99%

Use of Insurance Claims Data to Determine Prevalence and Confirm a Cluster of Sarcoidosis Cases in Vermont

et al. 2009

View full text Add to dashboard Cite

show abstract

Noninvasive testing of asymptomatic bilateral hilar adenopathy

Carr

Singer

Goldenheim³

et al. 1990

J Gen Intern Med

View full text Add to dashboard Cite

The diagnostic strategy for asymptomatic patients with persistent bilateral bilar adenopathy often involves invasive procedures. The authors used Bayesian analysis to: 1) estimate the relative prevalences of diseases causing bilateral bilar adenopathy; 2) assess changes in the prevalence of disease by race, the presence of other clinical symptoms, and geography; and 3) determine the value of relevant noninvasive tests, including the angiotensin-converting enzyme (ACE) assay, gallium scan, and purified protein derivative (PPD), in order to assess when a strategy of watchful waiting is appropriate. The analysis indicated that the ACE assay, particularly when paired with the PPD, can identify many patients who might safely be managed without immediate invasive biopsy. Patients who are ACE+ and PPD- have an estimated probability of sarcoidosis of 0.95 or greater; patients who are ACE- and PPD+ have a probability of tuberculosis of 0.86 if black, 0.79 if white. In contrast, gallium scanning has no diagnostic role in this clinical situation. Bronchoscopic or mediastinoscopic biopsy has a limited role for patients who are ACE+ PPD- or ACE- PPD+ because of limited sensitivity. Patients who are both ACE- and PPD-, particularly if white, may have a high enough risk of lymphoma to consider invasive biopsy.

show abstract

Current thoughts on the epidemiology and etiology of sarcoidosis

Siltzbach¹

1965

The American Journal of Medicine

View full text Add to dashboard Cite

Prevalence and Demographic Characteristics of Sarcoidosis in New York City

Cited by 5 publications

References 0 publications

Use of Insurance Claims Data to Determine Prevalence and Confirm a Cluster of Sarcoidosis Cases in Vermont

Use of Insurance Claims Data to Determine Prevalence and Confirm a Cluster of Sarcoidosis Cases in Vermont

Noninvasive testing of asymptomatic bilateral hilar adenopathy

Current thoughts on the epidemiology and etiology of sarcoidosis

Contact Info

Product

Resources

About